GlassScriptPhysician profile
Matias E Valsecchi
NPI 1235338328
$17,243.95
in general payments reported to CMS, 2019-2025
82 companies · $2,434 in 2025
The $2,434 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $1,766 · 2021: $2,851 · 2022: $2,618 · 2023: $2,915 · 2024: $2,540 · 2025: $2,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,875 · Education: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,875.32 |
| Education | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,857.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,351.72 | 2019-2025 | Opdivo, Reblozyl, Eliquis |
| Pfizer INC. | $1,122.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,028.61 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Genentech USA, INC. | $778.29 | 2019-2025 | Venclexta, Tecentriq, Lunsumio |
| Merck Sharp & Dohme LLC | $767.01 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $695.26 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $686.20 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Seagen INC. | $673.19 | 2019-2023 | Padcev, Adcetris |
| Astellas Pharma US INC | $577.02 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Janssen Biotech, INC. | $568.49 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Incyte Corporation | $551.83 | 2020-2025 | Jakafi, Pemazyre, Monjuvi |
| Amgen INC. | $524.66 | 2019-2023 | Lumakras |
| Glaxosmithkline, LLC. | $491.75 | 2020-2025 | Ojjaara, Zejula, Shingrix |
| Abbvie INC. | $445.38 | 2019-2025 | Venclexta |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matias Valsecchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.